Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration

Summary Objective Studies suggest nerve growth factor inhibitors (NGFi) relieve pain but may accelerate disease progression in some patients with osteoarthritis (OA). We sought cost and toxicity thresholds that would make NGFi a cost-effective treatment for moderate-to-severe knee OA. Design We used...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Osteoarthritis and cartilage 2016-05, Vol.24 (5), p.776-785
Hauptverfasser:	Losina, E, Michl, G, Collins, J.E, Hunter, D.J, Jordan, J.M, Yelin, E, Paltiel, A.D, Katz, J.N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - economics Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - economics Antibodies, Monoclonal, Humanized - therapeutic use Cost-Benefit Analysis Cost-effectiveness Disease Progression Drug Costs - statistics & numerical data Female Health Care Costs Health Services Research - methods Humans Infusions, Intravenous Injections, Subcutaneous Male Middle Aged Models, Econometric Nerve Growth Factor - antagonists & inhibitors Nerve growth factor inhibitors Osteoarthritis Osteoarthritis, Knee - drug therapy Osteoarthritis, Knee - economics Pain Measurement - methods Quality-Adjusted Life Years Rheumatology Self Administration - economics Tanezumab United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!